TR199501654A3 - - Google Patents

Info

Publication number
TR199501654A3
TR199501654A3 TR95/01654A TR9501654A TR199501654A3 TR 199501654 A3 TR199501654 A3 TR 199501654A3 TR 95/01654 A TR95/01654 A TR 95/01654A TR 9501654 A TR9501654 A TR 9501654A TR 199501654 A3 TR199501654 A3 TR 199501654A3
Authority
TR
Turkey
Prior art keywords
enzyme
host
prodrug
component
natural
Prior art date
Application number
TR95/01654A
Other languages
English (en)
Other versions
TR199501654A2 (tr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199501654(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed filed Critical
Publication of TR199501654A2 publication Critical patent/TR199501654A2/tr
Publication of TR199501654A3 publication Critical patent/TR199501654A3/tr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
TR95/01654A 1994-12-23 1995-12-22 Kimyasal bilesikler. TR199501654A2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds

Publications (2)

Publication Number Publication Date
TR199501654A2 TR199501654A2 (tr) 1996-07-21
TR199501654A3 true TR199501654A3 (tr) 1996-07-21

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
TR95/01654A TR199501654A2 (tr) 1994-12-23 1995-12-22 Kimyasal bilesikler.

Country Status (23)

Country Link
US (1) US5985281A (tr)
EP (1) EP0806964B1 (tr)
JP (1) JP3805365B2 (tr)
KR (1) KR100270650B1 (tr)
CN (1) CN1095677C (tr)
AT (1) ATE222124T1 (tr)
AU (1) AU701916B2 (tr)
BR (1) BR9510490B1 (tr)
CA (1) CA2205091A1 (tr)
CZ (1) CZ195297A3 (tr)
DE (1) DE69527805T2 (tr)
ES (1) ES2181805T3 (tr)
FI (1) FI972683A (tr)
HU (1) HUT77450A (tr)
IL (1) IL116511A0 (tr)
MX (1) MX9704575A (tr)
NO (1) NO972882L (tr)
NZ (1) NZ297529A (tr)
PL (1) PL184031B1 (tr)
RU (1) RU2189251C2 (tr)
SK (1) SK80997A3 (tr)
TR (1) TR199501654A2 (tr)
WO (1) WO1996020011A1 (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990036383A (ko) 1995-08-16 1999-05-25 크로우 캐씨 엘 화학적 화합물
TW406454B (en) 1996-10-10 2000-09-21 Berg Tech Inc High density connector and method of manufacture
WO1998035988A1 (en) * 1997-02-14 1998-08-20 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
WO2000016808A2 (en) * 1998-09-18 2000-03-30 Immunomedics, Inc. Antibody directed enzyme prodrug therapy (edept) with glucoronidase
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
JP2003509040A (ja) * 1999-09-17 2003-03-11 ジェンジム トランスジェニックス コーポレイション 遺伝子導入により産生された融合タンパク質
JP2006507839A (ja) * 2002-11-27 2006-03-09 ジーティーシー バイオセラピューティックス インコーポレイテッド 乳中に安定して産生される改変抗体およびその製造方法
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
EP2388272A1 (en) * 2005-10-21 2011-11-23 GTC Biotherapeutics, Inc. Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2037954A4 (en) * 2006-06-20 2011-09-14 Janssen Pharmaceutica Nv METHOD FOR MODULATING PHARMACOKINETICS AND METABOLISM OF THERAPEUTIC USE
CN101511774B (zh) 2006-10-03 2015-05-13 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的芥子气类化合物及其相关化合物的前药
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
EP2279003A4 (en) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF INFLAMMATORY DISEASES
US10745492B1 (en) 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
KR0185967B1 (ko) * 1989-01-23 1999-05-01 에프. 쥐. 엠. 헤르만스; 에이. 쥐. 제이. 베르미렌 치료용 약물의 부위 특이적 생체내 활성작용
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
AU674137B2 (en) * 1992-01-30 1996-12-12 Genzyme Limited Chiral synthesis with modified enzymes
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Also Published As

Publication number Publication date
NZ297529A (en) 1999-07-29
FI972683A0 (fi) 1997-06-19
HUT77450A (hu) 1998-04-28
ES2181805T3 (es) 2003-03-01
TR199501654A2 (tr) 1996-07-21
SK80997A3 (en) 1998-02-04
EP0806964B1 (en) 2002-08-14
NO972882L (no) 1997-08-19
MX9704575A (es) 1997-10-31
JP3805365B2 (ja) 2006-08-02
BR9510490B1 (pt) 2010-10-05
US5985281A (en) 1999-11-16
CN1095677C (zh) 2002-12-11
JPH10511547A (ja) 1998-11-10
ATE222124T1 (de) 2002-08-15
DE69527805T2 (de) 2003-04-24
CA2205091A1 (en) 1996-07-04
IL116511A0 (en) 1996-07-23
CN1171054A (zh) 1998-01-21
PL184031B1 (pl) 2002-08-30
EP0806964A1 (en) 1997-11-19
AU701916B2 (en) 1999-02-11
FI972683A (fi) 1997-06-19
KR100270650B1 (ko) 2000-11-01
PL320964A1 (en) 1997-11-24
BR9510490A (pt) 1998-01-13
AU4269796A (en) 1996-07-19
RU2189251C2 (ru) 2002-09-20
WO1996020011A1 (en) 1996-07-04
NO972882D0 (no) 1997-06-20
CZ195297A3 (en) 1997-12-17
DE69527805D1 (de) 2002-09-19

Similar Documents

Publication Publication Date Title
TR199501654A3 (tr)
ATE197903T1 (de) Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken
PL350658A1 (en) Medical preparations for the treatment of alpha−galactosidase a deficiency
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
AU563356B2 (en) Conjugate of enzyme and antibody
FI953529A (fi) Rokotteita, jotka sisältävät gangliosidi-KLH-konjugaattia ja QS-21-ainetta
IL155514A0 (en) Fusion cells and cytokine compositions for treatment of disease
WO1999065517A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
ZA97657B (en) Ligand directed enzyme prodrug therapy.
AU2002360350A1 (en) Peptides that home to tumor lymphatic vasculature and methods of using same
MX9800967A (es) Compuestos quimicos.
AU6182994A (en) Bifunctional glycoproteins having a modified carbohydrate complement, and their use in tumor-selective therapy
AU3991899A (en) Verotoxin b subunit for immunization
ZA200107368B (en) Immunostimulant bacterial membrane fractions in cancer treatment
AU6942896A (en) Use of muteins of wild-type cytokines as immunogens
MX9802809A (es) Ureasa para el tratamiento de infecciones de helicobacter pylori.
AU3796297A (en) Pituitary differentiation factor and methods of use thereof
TW332816B (en) Peptide and carbohydrate